Skip to main content

Table 2 Systemic immune activation, inflammation, microbial translocation, proinflammatory cytokines, intestinal damage and inflammation biomarkers

From: Association of intestinal and systemic inflammatory biomarkers with immune reconstitution in HIV+ patients on ART

 

HIV- (n = 14)

IR (n = 18)

INR (n = 18)

p value

T-CELL IMMUNE ACTIVATION

CD4+ T-cells

  HLA-DR+ expression, %

59 (16.2–92.9)

61.8 (22.7–84.3)

58.1 (37.3–75.8)

0.949a

  HLA-DR+, MFI

7500 (6646–10,826)

9874 (5474–14,796)

7067 (5591–13,789)

0.802a

  CD38+ expression, %

51.2 (42.9–56.1)

47.3 (35.2–54.6)

39.1 (25.3–42.7)

< 0.05a

  CD38+, MFI

5203 (4322–6001)

4771 (4574–5666)

4930 (4475.5–5766.5)

0.892a

  HLA-DR+ and CD38+ co-expression, %

34.7 (31.9–52.3)

40.8 (23.1–48.1)

18.1 (9.8–23.8)

< 0.01a

  HLA-DR+ and CD38+, MFI

11,380 (7002.5–12,585.5)

5310 (4657–24,752)

9661 (7280–18,114)

0.727a

CD8+ T-cells

  HLA-DR+ expression, %

37.8 (30.8–45.5)

23 (13.4–57.9)

35 (16.7–57.5)

0.648a

  HLA-DR+, MFI

7019.5 (5789–8557)

10,965 (9207–17,730)

9696 (7193.5–12,288.5)

< 0.05a

  CD38+ expression, %

46 (33.2–50.4)

33.6 (23–50.3)

36.2 (24–43.4)

0.618a

  CD38+, MFI

4098 (3250–5171)

3724 (3342–3791)

3684 (3360–4640)

0.712a

  HLA-DR+ and CD38+ co-expression, %

11.1 (6.6–13.2)

13.8 (11.6–15.8)

12.4 (6.4–26.3)

0.466a

  HLA-DR+ and CD38+, MFI

8840 (7816–12,020)

13,987 (10852–19,953)

14,066 (11643–18,748)

0.186a

INNATE IMMUNE ACTIVATION

 sCD14, ng/mL

55.6 (12.2–199.6)

184.7 (109.4–329.9)

238.8 (196.2–378.9)

< 0.01a

 sCD163, ng/mL

192.1 (158.3–254.9)

242.5 (141.8–339.8)

230.8 (94.5–385.9)

0.789a

SYSTEMIC INFLAMMATION

 C-reactive protein, mg/dL

0.27 (0.16–1.04)

1.24 (0.67–2.09)

1.63 (0.96–4.53)

< 0.05a

 C- reactive protein (≥ 3.0 mg/dL), N (%)

1 (7.1%)

3 (16.7%)

6 (33.3%)

0.168b

MICROBIAL TRANSLOCATION

 Lipopolysaccharide, pg/mL

1098.7 (182.8–2876.2)

588.6 (257.1–1931)

979.2 (409.9–2281.8)

0.644a

PROINFLAMMATORY CYTOKINES

 Fecal IL-1β, pg/mL

10.4 (10.4–11.7)

47.1 (16.9–114.4)

44 (28.9–176.3)

< 0.001a

 Fecal IL-8, pg/mL

8.21 (8.2–16.6)

116.8 (21.9–234.7)

88.7 (43.8–204.5)

< 0.001a

 Fecal IL-18, pg/mL

40.7 (40.7–40.7)

66.8 (40.7–487)

132.8 (40.7454.6)

< 0.01a

 IL-1β, pg/mL

11.1 (10.4–11.8)

11.8 (10.4–16.9)

16.9 (10.4–21.9)

0.368a

 IL-8, pg/mL

16.58 (8.2–22)

16.6 (8.21–22)

16.6 (8.2–27.3)

0.845a

 IL-18, pg/mL

89.7 (40.7–192.2)

158 (96.2–257.7)

173.4 (96.2–316.12)

0.153a

INTESTINAL DAMAGE

 I-FABP, ng/mL

6.33 (0.0–126.4)

31.2 (8.5–283.2)

53.6 (27.3–216.2)

0.164a

 sST2, ng/mL

28.6 (23.6–35.6)

31.1 (23.4–39.3)

33.1 (27.6–38.5)

0.603a

INTESTINAL INFLAMMATION

 Fecal lactoferrin, μg/g

2.0 (1.8–2.5)

2.5 (1.9–2.9)

3.1 (2.2–4.0)

< 0.05a

 Fecal lactoferrin (≥ 5.6 μg/g), N (%)

0 (0%)

1 (5.6%)

3 (17%)

0.202b

 Fecal calprotectin, μg/g

2.7 (2.6–2.9)

2.7 (2.6–2.9)

3.1 (2.7–3.4)

< 0.05a

 Secretory IgA, mg/L

8566.5 (5066.9–10,042.2)

10,122.1 (5721–10,844.8)

7791.2 (6257.4–11,329.9)

0.82a

  1. aKruskall-Wallis test with Bonferroni correction, bChi square. All values are expressed as median and interquartile range, except for those where another measurement expression is specified